Ozempic vs Wegovy UK:
What's the Difference?

The basics: why two products for the same molecule?

Ozempic and Wegovy both contain semaglutide, manufactured by Novo Nordisk. Semaglutide was first developed and licensed as a treatment for type 2 diabetes under the brand name Ozempic. When clinical trials demonstrated significant weight loss in patients using semaglutide, Novo Nordisk developed Wegovy as a separate product at a higher dose, specifically for chronic weight management.

The two products received separate MHRA marketing authorisations and separate NICE appraisals. They are legally distinct medicines with different Summary of Product Characteristics (SmPC) documents, different prescribing indications and different NHS commissioning pathways.

Head-to-head comparison

On-label vs off-label prescribing

This distinction is crucial for understanding how the two products are used in the UK.

Ozempic: on-label for diabetes, off-label for weight loss

Ozempic's MHRA marketing authorisation is for type 2 diabetes. When a clinician prescribes Ozempic for weight management, this is considered off-label prescribing. Off-label prescribing is legal in the UK and occurs regularly in medical practice, but it means the prescriber takes greater clinical responsibility for the decision.

The NHS does not routinely fund off-label Ozempic for weight loss. However, some private clinics prescribe Ozempic off-label for weight management, often because it has historically been cheaper or more readily available than Wegovy.

Wegovy: on-label for weight management

Wegovy's MHRA licence specifically covers weight management in adults with obesity or overweight with at least one weight-related comorbidity. This on-label indication means that NICE has been able to appraise Wegovy for this purpose and recommend NHS funding through specialist services.

Dose comparison: why 2.4 mg matters

The higher maintenance dose in Wegovy (2.4 mg) compared with Ozempic (standard 1 mg, maximum 2 mg) is the primary pharmacological difference between the two products. This higher dose produces greater appetite suppression and, on average, more weight loss.

In the STEP 1 clinical trial, participants taking Wegovy 2.4 mg lost an average of 14.9 per cent of their body weight over 68 weeks. In the SUSTAIN trials, Ozempic at 1 mg produced an average weight loss of approximately 4.5 to 6.5 kg (around 5 to 7 per cent body weight) over 30 to 56 weeks. The difference reflects the dose-response relationship of semaglutide.

NHS access: two very different pathways

Getting Ozempic on the NHS

Ozempic is available through standard GP prescribing for patients with type 2 diabetes who meet NICE NG28 criteria. This typically requires:

• A confirmed type 2 diabetes diagnosis
• HbA1c above target despite metformin and at least one other oral agent
• BMI of 35 or above (adjusted for ethnicity)

The pathway is relatively straightforward and does not require referral to a specialist service.

Getting Wegovy on the NHS

Wegovy requires referral to a Tier 3 specialist weight management service. The process involves a GP referral, assessment by a multidisciplinary team, enrolment in a structured behavioural programme and meeting the NICE TA875 eligibility criteria. Waiting times for Tier 3 services vary significantly across the country.

Cost comparison: NHS and private

NHS costs

On the NHS, both medications cost the patient the standard prescription charge (£9.90 per item in England, free in Scotland, Wales and Northern Ireland). However, the cost to the NHS differs significantly:

• Ozempic 1 mg: Approximately £73 per pen (NHS drug tariff price)
• Wegovy 2.4 mg: Approximately £73 per pen (NHS drug tariff price)

Although the per-pen costs are similar, Wegovy requires the additional infrastructure of Tier 3 specialist services, making the overall cost to the NHS higher per patient.

Private costs

Private providers are listed in our UK weight loss clinics guide.

Side effects: any difference?

Because both products contain semaglutide, the side-effect profile is essentially the same. However, the higher maintenance dose in Wegovy means that gastrointestinal side effects tend to be more frequent and may be more pronounced. The STEP trials reported nausea in approximately 44 per cent of Wegovy participants, compared with around 20 per cent in SUSTAIN trials for Ozempic at 1 mg.

The gradual 16-week dose escalation in Wegovy (compared with 8 weeks for Ozempic) is designed to mitigate this difference. For detailed guidance on managing side effects, see our Ozempic side effects guide and comprehensive GLP-1 side effects guide.

Which should you choose?

Can you switch between Ozempic and Wegovy?

Yes, switching from Ozempic to Wegovy (or vice versa) is possible and is sometimes recommended by clinicians. Because both contain semaglutide, the transition is generally straightforward. When switching from Ozempic to Wegovy, your clinician will typically start you at the nearest equivalent dose rather than restarting from 0.25 mg. When switching from Wegovy to Ozempic (for example, if you develop type 2 diabetes or if Wegovy becomes unavailable), the dose will be adjusted downwards.

Never switch between medications or adjust doses without consulting your prescriber.

Frequently asked questions

Is Ozempic cheaper than Wegovy?

On the private market, Ozempic at its standard 1 mg dose is typically slightly cheaper than Wegovy at its 2.4 mg maintenance dose. However, the difference is modest (roughly £30 to £50 per month). On the NHS, the patient cost is the same standard prescription charge.

Can I use Ozempic for weight loss instead of Wegovy?

Technically, yes — some private clinics prescribe Ozempic off-label for weight loss. However, you would be using a lower dose of semaglutide than Wegovy provides, potentially achieving less weight loss. Additionally, off-label use is not funded by the NHS for weight management.

Are there supply issues with either product?

Both Ozempic and Wegovy experienced intermittent supply difficulties during 2023 and 2024. As of early 2026, supply has broadly stabilised for both products, although specific pen strengths may occasionally be temporarily unavailable. NHS England has issued guidance prioritising Ozempic supply for patients with type 2 diabetes.